The Psychedelics Newsletter, Issue 127

PSYCH SYMPOSIUM RETURNS TO LONDON

After a sold-out conference in 2022, PSYCH Symposium is returning to bring together leading investors, regulators, scientists and industry leaders who are looking to transform the future of healthcare through psychedelic medicine.

The event has become one of the most highly anticipated conferences in the field of psychedelic healthcare, attracting industry leaders and professionals from around the world. The Symposium provides a platform for experts to discuss the latest research, development and commercialisation of psychedelics for various medical conditions.

PSYCH Symposium aims to promote the integration of psychedelics into mainstream medicine, and attendees will have the opportunity to connect with leading researchers in the field, network with peers and learn about the latest developments in psychedelic research and therapy.

READ MORE

INSIDE THE UK-FUNDED KETAMINE STUDY FOR ALCOHOL USE DISORDER

Led by Awakn Life Sciences, it will be the largest clinical trial of ketamine-assisted therapy to date.

READ MORE

AMERICAN PHARMACISTS ASSOCIATION SUPPORTS DRUG DECRIMINALISATION

Awakn will now contribute just ￡800,000 to its Phase III study into alcohol use disorder.

READ MORE

BUSINESS AND INVESTMENT

• Reunion Neuroscience struggles to?remain Nasdaq listed.?This year, the company’s share price is down 28%.
• University of Exeter launches postgraduate course in?psychedelic therapy.?The online course will focus on science and philosophy.
• Apex Labs granted approval for 160?patient psilocybin study.?The Phase II clinical trial hopes to treat severe depression within diagnosed PTSD.
• Filament Health and PharmAla?release MDMA capsules.?The product will be distributed for clinical trials.

On Thursday, 6 July, industry leaders will converge at the iconic British Museum for PSYCH Symposium: London 2023. Tickets on sale for ￡329 + VAT.

TICKET REGISTRATION

SCIENCE AND RESEARCH

• The neural entropy increase elicited by?psychedelic drugs.?Understanding the mechanisms that trigger changes in consciousness.
• An overview of?5-MeO-DMT.?The potent psychedelic compound is found in the parotid glands of the Bufo alvarius toad.o five weeks later.

REGULATION AND LEGISLATION

• Oregon Health Authority licenses first?psilocybin testing facility.?The laboratory will test product potency in the state’s adult-use market.
• Colorado senators pass bill on the?framework for psilocybin services.?It hopes to formalise rules for the provision and access of psilocybin.

Would your organisation benefit from engaging with Europe’s psychedelic medicine community?

Partnership with PSYCH provides the opportunity to engage an audience ready to support the development of psychedelic healthcare.

Previous partners include COMPASS Pathways, Beckley Psytech and Awakn Life Sciences.

For more information and to request the PSYCH media kit, please email?[email protected].

REQUEST MEDIA KIT

ARTICLES OF INTEREST

• Poor mental health is damaging?the UK economy.?In the final quarter of 2022, employee absence cost companies ￡12.3 billion.
• NHS fails to treat 250,000 children with?mental health conditions.?One-third of referrals are denied treatment.